[go: up one dir, main page]

WO2005007144A3 - Method of diagnosis and treatment for asthma based on haplotype association - Google Patents

Method of diagnosis and treatment for asthma based on haplotype association Download PDF

Info

Publication number
WO2005007144A3
WO2005007144A3 PCT/US2004/022446 US2004022446W WO2005007144A3 WO 2005007144 A3 WO2005007144 A3 WO 2005007144A3 US 2004022446 W US2004022446 W US 2004022446W WO 2005007144 A3 WO2005007144 A3 WO 2005007144A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
asthma
diagnosis
asthma based
haplotype association
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2004/022446
Other languages
French (fr)
Other versions
WO2005007144A2 (en
Inventor
Hakon Hakonarson
Mark E Gurney
Eva Halapi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Decode Genetics ehf
Original Assignee
Decode Genetics ehf
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Decode Genetics ehf filed Critical Decode Genetics ehf
Priority to CA002532203A priority Critical patent/CA2532203A1/en
Priority to AU2004257748A priority patent/AU2004257748B2/en
Priority to MXPA06000514A priority patent/MXPA06000514A/en
Priority to EP04778119A priority patent/EP1646372A2/en
Priority to US11/043,752 priority patent/US20060014165A1/en
Publication of WO2005007144A2 publication Critical patent/WO2005007144A2/en
Publication of WO2005007144A3 publication Critical patent/WO2005007144A3/en
Anticipated expiration legal-status Critical
Priority to US11/881,406 priority patent/US20080146540A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Methods for diagnosis of asthma or a susceptibility to asthma based on detection of at-risk haplotypes associated with MAP3K9 are disclosed. Also methods for treatment of asthma or a susceptibility to asthma based on detection of at-risk haplotypes associated with MAP3K9 are disclosed. In particular, pathway targeting for treating individuals who are at-risk of developing asmtha are described. In certain aspects, MLK1 inhibitors are used in treatment methods.
PCT/US2004/022446 2003-07-14 2004-07-14 Method of diagnosis and treatment for asthma based on haplotype association Ceased WO2005007144A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
CA002532203A CA2532203A1 (en) 2003-07-14 2004-07-14 Method of diagnosis and treatment for asthma based on haplotype association
AU2004257748A AU2004257748B2 (en) 2003-07-14 2004-07-14 Method of diagnosis and treatment for asthma based on haplotype association
MXPA06000514A MXPA06000514A (en) 2003-07-14 2004-07-14 Method of diagnosis and treatment for asthma based on haplotype association.
EP04778119A EP1646372A2 (en) 2003-07-14 2004-07-14 Methods of diagnosis and treatment for asthma based on haplotype association
US11/043,752 US20060014165A1 (en) 2003-07-14 2005-01-26 Methods of diagnosis and treatment for asthma and other respiratory diseases based on haplotype association
US11/881,406 US20080146540A1 (en) 2003-07-14 2007-07-26 Methods of diagnosis and treatment for asthma, allergic rhinitis and other respiratory diseases based on haplotype association

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US48707203P 2003-07-14 2003-07-14
US60/487,072 2003-07-14
US55961104P 2004-04-05 2004-04-05
US60/559,611 2004-04-05

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/043,752 Continuation-In-Part US20060014165A1 (en) 2003-07-14 2005-01-26 Methods of diagnosis and treatment for asthma and other respiratory diseases based on haplotype association

Publications (2)

Publication Number Publication Date
WO2005007144A2 WO2005007144A2 (en) 2005-01-27
WO2005007144A3 true WO2005007144A3 (en) 2005-06-16

Family

ID=34083403

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/022446 Ceased WO2005007144A2 (en) 2003-07-14 2004-07-14 Method of diagnosis and treatment for asthma based on haplotype association

Country Status (5)

Country Link
EP (1) EP1646372A2 (en)
AU (1) AU2004257748B2 (en)
CA (1) CA2532203A1 (en)
MX (1) MXPA06000514A (en)
WO (1) WO2005007144A2 (en)

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8691849B2 (en) 2008-09-02 2014-04-08 Janssen Pharmaceuticals, Inc. 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors
US8691813B2 (en) 2008-11-28 2014-04-08 Janssen Pharmaceuticals, Inc. Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors
US8697689B2 (en) 2008-10-16 2014-04-15 Janssen Pharmaceuticals, Inc. Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors
US8722894B2 (en) 2007-09-14 2014-05-13 Janssen Pharmaceuticals, Inc. 1,3-disubstituted-4-phenyl-1H-pyridin-2-ones
US8748621B2 (en) 2007-09-14 2014-06-10 Janssen Pharmaceuticals, Inc. 1,3-disubstituted 4-(aryl-X-phenyl)-1H-pyridin-2-ones
US8785486B2 (en) 2007-11-14 2014-07-22 Janssen Pharmaceuticals, Inc. Imidazo[1,2-A]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
US8841323B2 (en) 2006-03-15 2014-09-23 Janssen Pharmaceuticals, Inc. 1, 4-disubstituted 3-cyano-pyridone derivatives and their use as positive allosteric modulators of MGLUR2-receptors
US8906939B2 (en) 2007-03-07 2014-12-09 Janssen Pharmaceuticals, Inc. 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
US8937060B2 (en) 2009-05-12 2015-01-20 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo [4,3-A] pyridine derivatives and their use for the treatment of prevention of neurological and psychiatric disorders
US8946205B2 (en) 2009-05-12 2015-02-03 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
US8993591B2 (en) 2010-11-08 2015-03-31 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a] pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors
US9012448B2 (en) 2010-11-08 2015-04-21 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors
US9085577B2 (en) 2009-05-12 2015-07-21 Janssen Pharmaceuticals, Inc. 7-aryl-1,2,4-triazolo[4,3-A]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
US9114138B2 (en) 2007-09-14 2015-08-25 Janssen Pharmaceuticals, Inc. 1′,3′-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2H,1′H-[1,4′] bipyridinyl-2′-ones
US9271967B2 (en) 2010-11-08 2016-03-01 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060014165A1 (en) * 2003-07-14 2006-01-19 Decode Genetics Ehf. Methods of diagnosis and treatment for asthma and other respiratory diseases based on haplotype association
US20070299027A1 (en) * 2006-01-26 2007-12-27 Gene Hung Compositions and their uses directed to huntingtin
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
JO3368B1 (en) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv 6, 7- dihydropyrazolu [5,1-a] pyrazine-4 (5 hands) -on compounds and their use as negative excretory regulators of Miglore 2 receptors.
JO3367B1 (en) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv 1,2,4-TRIAZOLO[4,3-a]PYRIDINE COMPOUNDS AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
KR20200036063A (en) 2014-01-21 2020-04-06 얀센 파마슈티카 엔.브이. Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
EP3096790B1 (en) 2014-01-21 2019-07-10 Janssen Pharmaceutica, N.V. Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997049406A1 (en) * 1996-06-25 1997-12-31 Cephalon, Inc. Use of k-252a derivative for the treatment of peripheral or central nerve disorders, and cytokine overproduction
WO2002014536A2 (en) * 2000-08-11 2002-02-21 Cephalon, Inc. Odulating multiple lineage kinase proteins
WO2003064428A1 (en) * 2002-01-29 2003-08-07 H. Lundbeck A/S Furano- and thienopyrimidines as neurokinase inhibitors

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL144515A0 (en) * 2000-07-31 2002-05-23 Pfizer Prod Inc A pcr-based multiplex assay for determining haplotype

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997049406A1 (en) * 1996-06-25 1997-12-31 Cephalon, Inc. Use of k-252a derivative for the treatment of peripheral or central nerve disorders, and cytokine overproduction
WO2002014536A2 (en) * 2000-08-11 2002-02-21 Cephalon, Inc. Odulating multiple lineage kinase proteins
WO2003064428A1 (en) * 2002-01-29 2003-08-07 H. Lundbeck A/S Furano- and thienopyrimidines as neurokinase inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HAKONARSON HAKON ET AL: "A major susceptibility gene for asthma maps to chromosome 14q24", AMERICAN JOURNAL OF HUMAN GENETICS, vol. 71, no. 3, September 2002 (2002-09-01), pages 483 - 491, XP008039565, ISSN: 0002-9297 *

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8841323B2 (en) 2006-03-15 2014-09-23 Janssen Pharmaceuticals, Inc. 1, 4-disubstituted 3-cyano-pyridone derivatives and their use as positive allosteric modulators of MGLUR2-receptors
US9266834B2 (en) 2006-03-15 2016-02-23 Janssen Pharmaceuticals, Inc. 1, 4-disubstituted 3-cyano-pyridone derivatives and their use as positive allosteric modulators of MGLUR2-receptors
US8906939B2 (en) 2007-03-07 2014-12-09 Janssen Pharmaceuticals, Inc. 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
US9114138B2 (en) 2007-09-14 2015-08-25 Janssen Pharmaceuticals, Inc. 1′,3′-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2H,1′H-[1,4′] bipyridinyl-2′-ones
US8722894B2 (en) 2007-09-14 2014-05-13 Janssen Pharmaceuticals, Inc. 1,3-disubstituted-4-phenyl-1H-pyridin-2-ones
US8748621B2 (en) 2007-09-14 2014-06-10 Janssen Pharmaceuticals, Inc. 1,3-disubstituted 4-(aryl-X-phenyl)-1H-pyridin-2-ones
US9132122B2 (en) 2007-09-14 2015-09-15 Janssen Pharmaceuticals, Inc. 1′,3′-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2H,1′H-[1,4′]bipyridinyl-2′-ones
US8785486B2 (en) 2007-11-14 2014-07-22 Janssen Pharmaceuticals, Inc. Imidazo[1,2-A]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
US8691849B2 (en) 2008-09-02 2014-04-08 Janssen Pharmaceuticals, Inc. 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors
US8697689B2 (en) 2008-10-16 2014-04-15 Janssen Pharmaceuticals, Inc. Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors
US8691813B2 (en) 2008-11-28 2014-04-08 Janssen Pharmaceuticals, Inc. Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors
US8937060B2 (en) 2009-05-12 2015-01-20 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo [4,3-A] pyridine derivatives and their use for the treatment of prevention of neurological and psychiatric disorders
US9085577B2 (en) 2009-05-12 2015-07-21 Janssen Pharmaceuticals, Inc. 7-aryl-1,2,4-triazolo[4,3-A]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
US9226930B2 (en) 2009-05-12 2016-01-05 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo [4,3-a] pyridine derivatives and their use for the treatment of prevention of neurological and psychiatric disorders
US8946205B2 (en) 2009-05-12 2015-02-03 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
US9012448B2 (en) 2010-11-08 2015-04-21 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors
US8993591B2 (en) 2010-11-08 2015-03-31 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a] pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors
US9271967B2 (en) 2010-11-08 2016-03-01 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors

Also Published As

Publication number Publication date
WO2005007144A2 (en) 2005-01-27
EP1646372A2 (en) 2006-04-19
AU2004257748B2 (en) 2008-10-30
MXPA06000514A (en) 2006-06-20
AU2004257748A1 (en) 2005-01-27
CA2532203A1 (en) 2005-01-27

Similar Documents

Publication Publication Date Title
WO2005007144A3 (en) Method of diagnosis and treatment for asthma based on haplotype association
WO2006081555A3 (en) Methods of diagnosis and treatment for asthma, allergic rhinitis and other respiratory diseases based on haplotype association
GB0203446D0 (en) Detection and/or monitoring of synuclein-related diseases
WO2008140774A3 (en) Methods for diagnosing and treating prostate and lung cancer
WO2005062770A3 (en) Method for conducting pharmacogenomics-based studies
WO2004090539A3 (en) Methods of determining efficacy of treatments of inflammatory diseases of the bowel
WO2003070700A3 (en) Compositions and methods for determining the susceptibility of a pathogenic virus to protease inhibitors
SG146653A1 (en) Methods and reagents for the treatment of immunoinflammatory disorders
IL183284A0 (en) Methods and compositions for treating ocular disorders
WO2007041245A3 (en) Biomarkers for multiple sclerosis and methods of use thereof
WO2005054503A3 (en) Biomarkers for graft rejection
WO2004055196A3 (en) Method for identifying risk of breast cancer and treatments thereof
AU2002315411A1 (en) Detection and treatment of prostate cancer
WO2004003512A3 (en) Compositions and methods for determining the susceptibility of a pathogenic virus to protease inhibitors
WO2004003514A3 (en) Compositions and methods for determining the susceptibility of a pathogenic virus to protease inhibitors
WO2009027703A3 (en) Identifying organ damage
WO2010102160A3 (en) Diagnostic method using palb2
WO2007076437A3 (en) C3-convertase inhibitors for the prevention and treatment of age-related macular degeneration in patients with at risk variants of complement factor h
WO2007081790A3 (en) Methods for diagnosing and treating prostate cancer
DK1441708T3 (en) Compositions and Methods for Increasing Susceptibility to Therapies Using Aldehyde Dehydrogenase Inhibitors and Treatment of Alcoholism
WO2007095287A3 (en) Protective complement proteins and age-related macular degeneration
WO2004038045A3 (en) Method for diagnosing diffuse-type gastric cancer
WO2005062706A3 (en) Methods of predicting a benefit of antioxidant therapy for prevention of cardiovascular disease in hyperglycemic patients
NO20092078L (en) Procedure for the treatment of alcohol abuse, addiction and addiction
WO2006053955A3 (en) Method and kit for detecting a risk of essential arterial hypertension

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 11043752

Country of ref document: US

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2532203

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2006/000514

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2004257748

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 544730

Country of ref document: NZ

WWP Wipo information: published in national office

Ref document number: 11043752

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2004257748

Country of ref document: AU

Date of ref document: 20040714

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004257748

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2004778119

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2004778119

Country of ref document: EP